首页> 外文期刊>The British Journal of Surgery >Novel bulking agent for faecal incontinence.
【24h】

Novel bulking agent for faecal incontinence.

机译:用于粪便失禁的新型填充剂。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Various injectable bulking agents have been used for the treatment of faecal incontinence (FI). However, encouraging early results are not maintained over time. This study aimed to assess short- and medium-term results of a new bulking agent for the treatment of FI. METHODS: The Gatekeeper() prosthesis comprises a thin solid polyacrylonitrile cylinder that becomes thicker, shorter and softer within 24 h after implantation. Fourteen patients with FI underwent treatment with Gatekeeper() under local anaesthesia. Four prostheses were implanted in the intersphincteric space in each patient, under endoanal ultrasound guidance. Number of episodes of major FI, Cleveland Clinic FI score (CCFIS), Vaizey score, anorectal manometry, endoanal ultrasonography (EUS), health status and quality of life (Short Form 36 and Faecal Incontinence Quality of Life questionnaires) were assessed before and after treatment. RESULTS: Mean(s.d.) follow-up was 33.5(12.4) months. There were no complications. There was a significant decrease in major FI episodes from 7.1(7.4) per week at baseline to 1.4(4.0), 1.0(3.2) and 0.4(0.6) per week respectively at 1-month, 3-month and last follow-up (P = 0.002). CCFIS improved significantly from 12.7(3.3) to 4.1(3.0), 3.9(2.6) and 5.1(3.0) respectively (P < 0.001), and Vaizey score from 15.4(3.3) to 7.1(3.9), 4.7(3.0) and 6.9(5.0) respectively (P = 0.010). Soiling and ability to postpone defaecation improved significantly, and patients reported significant improvement in health status and quality of life. At follow-up, manometric parameters had not changed and EUS did not demonstrate any prosthesis dislocation. CONCLUSION: The Gatekeeper() anal implant seemed safe, reliable and effective. Initial clinical improvement was maintained over time, and follow-up data were encouraging.
机译:背景:各种可注射填充剂已用于治疗大便失禁(FI)。但是,随着时间的推移,令人鼓舞的早期结果并未得到保持。这项研究旨在评估新型填充剂治疗FI的近期和中期结果。方法:Gatekeeper()假体包括一个薄的实心聚丙烯腈圆柱体,该圆柱体在植入后24小时内变厚,变短和变软。 14位FI的患者在局部麻醉下接受了Gatekeeper()治疗。在鼻内超声的指导下,在每个患者的括约肌间隙中植入四个假体。前后评估主要FI,克利夫兰诊所FI评分(CCFIS),Vaizey评分,肛门直肠测压,肛门内超声(EUS),健康状况和生活质量(简短表格36和粪便失禁生活质量问卷)的发作次数。治疗。结果:平均随访时间为33.5(12.4)个月。没有并发症。在1个月,3个月和最后一次随访时,主要FI发生率分别从基线的每周7.1(7.4)降至每周的1.4(4.0),1.0(3.2)和0.4(0.6)( P = 0.002)。 CCFIS分别从12.7(3.3)显着提高到4.1(3.0),3.9(2.6)和5.1(3.0)(P <0.001),并且Vaizey分数从15.4(3.3)分别提高到7.1(3.9),4.7(3.0)和6.9分别为(5.0)(P = 0.010)。污染和推迟排便的能力得到显着改善,患者报告健康状况和生活质量得到显着改善。随访时,测压参数未改变,EUS未显示任何假体脱位。结论:Gatekeeper()肛门植入物似乎是安全,可靠和有效的。随着时间的推移,最初的临床改善得以保持,随访数据令人鼓舞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号